Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.78M | 397.00K | 705.00K | 71.00K | 0.00 |
Gross Profit | 1.20M | 397.00K | 705.00K | 71.00K | 0.00 |
EBITDA | -31.12M | -72.36M | -89.02M | -55.87M | -19.27M |
Net Income | -51.38M | -78.69M | -88.30M | -213.07M | -43.77M |
Balance Sheet | |||||
Total Assets | 28.33M | 75.79M | 163.93M | 240.65M | 110.18M |
Cash, Cash Equivalents and Short-Term Investments | 11.77M | 43.93M | 105.23M | 211.99M | 103.12M |
Total Debt | 8.06M | 8.85M | 10.76M | 7.04M | 2.88M |
Total Liabilities | 44.33M | 51.33M | 52.37M | 30.36M | 204.36M |
Stockholders Equity | -1.68M | 40.20M | 122.01M | 211.62M | -94.43M |
Cash Flow | |||||
Free Cash Flow | -19.84M | -72.03M | -107.54M | -62.85M | -21.15M |
Operating Cash Flow | -19.73M | -70.29M | -88.71M | -56.97M | -19.00M |
Investing Cash Flow | 2.14M | -5.35M | -32.61M | -6.04M | 8.39M |
Financing Cash Flow | 5.82M | -5.61M | 15.89M | 170.96M | 100.37M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | HK$1.92B | 48.36 | 4.92% | ― | 38.48% | ― | |
65 Neutral | ¥342.43B | 8.69 | -3.93% | 2.47% | 11.18% | -19.47% | |
57 Neutral | HK$917.05M | ― | -266.90% | ― | ― | 31.23% | |
53 Neutral | HK$1.44B | ― | -32.59% | ― | -79.65% | 37.50% | |
52 Neutral | HK$4.01B | ― | -75.64% | ― | 42.21% | 29.52% | |
51 Neutral | HK$765.30M | ― | ― | -1.73% | -689.53% | ||
49 Neutral | HK$10.84B | ― | -22.23% | ― | -14.17% | 76.00% |
Sirnaomics Ltd. announced the resignation of Dr. Cheung Hoi Yu from his roles as an independent non-executive director and various committee positions, effective October 18, 2025. Dr. Yu is stepping down to focus on other commitments, and the company is actively seeking suitable candidates to fill the resulting vacancies to maintain compliance with listing regulations.
Sirnaomics Ltd. has announced the appointment of Mr. Ouyang Yunlong as a non-executive director and Dr. Zhang Peng as an independent non-executive director, both effective from July 3, 2025. These appointments are expected to strengthen the company’s leadership in the biomedical industry, leveraging Mr. Ouyang’s extensive experience in financial management and venture capital investment, and Dr. Zhang’s expertise, to enhance strategic decision-making and industry positioning.
Sirnaomics Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement underscores the company’s commitment to strong governance and strategic leadership, which could enhance its position in the biotechnology sector and potentially impact its stakeholders positively.
Sirnaomics Ltd. announced the successful passing of all resolutions at its Annual General Meeting held on June 20, 2025. Key decisions included the re-election of directors, re-appointment of auditors, and granting mandates for share issuance and buybacks, reflecting strong shareholder support and strategic positioning for future growth.
Sirnaomics Ltd. has announced the composition of its board of directors, highlighting key roles and committee memberships. The board includes Dr. Poon Hung Fai as the CEO and executive director, with Ms. Monin Ung serving as the chairlady. The announcement also details the structure of the company’s audit, nomination, and remuneration committees, which are crucial for corporate governance and strategic decision-making.
Sirnaomics Ltd. has amended the terms of reference for its Nomination Committee, initially adopted in December 2021. The committee, which plays a crucial role in the governance of the company, is composed of at least three directors, with a majority being independent non-executive directors and at least one member of a different gender. This amendment underscores the company’s commitment to diversity and effective governance, potentially enhancing its industry positioning and stakeholder confidence.